AI
NMTR

Atom Investors’s 9 Meters Biopharma NMTR Stock Holding History

Atom Investors’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,117
Closed -$27K – 394
2022
Q2 		$27K Buy
+5,117
New +$48.2K 0.01% 241
2022
Q1 		– Sell
-1,980
Closed -$39K – 355
2021
Q4 		$39K Buy
+1,980
New +$44.3K 0.01% 252

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Atom Investors's NMTR Position: Q3 2022 in Review

Atom Investors sold out of 9 Meters Biopharma (NMTR) in Q3 2022, closing a stake of 5,117 shares — an estimated $27K sold.

Atom Investors first reported a position in NMTR in Q4 2021 and held it in 2 quarters. The position peaked at $39K in Q4 2021. 74 funds tracked by Wall St. Rank hold NMTR as of Q3 2022.

  • Atom Investors reported no remaining 9 Meters Biopharma position as of Q3 2022 after selling out during the quarter.
  • Atom Investors sold 5,117 9 Meters Biopharma shares in Q3 2022, an estimated $27K.
  • Atom Investors first reported a position in 9 Meters Biopharma in Q4 2021 and held it in 2 quarters.
  • Atom Investors's 9 Meters Biopharma position peaked at $39K in Q4 2021.
  • 74 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2022.

Based on Atom Investors's 13F filing for Q3 2022, filed 8 Nov 2022.